



US009408899B2

(12) **United States Patent**
McLeod et al.

(10) **Patent No.:** US 9,408,899 B2
(45) **Date of Patent:** Aug. 9, 2016

(54) **VACCINES AGAINST *TOXOPLASMA GONDII***

(75) Inventors: **Rima McLeod**, Chicago, IL (US); **Tze Guan Tan**, Cambridge, MA (US); **Jeffery L. Alexander**, San Diego, CA (US); **Hua Cong**, Shandong (CN); **William H. Witola**, Auburn, AL (US); **Kamal El Bissati**, Chicago, IL (US); **Ernest J. Mui**, Chicago, IL (US); **Steven G. Reed**, Bellevue, WA (US)

(73) Assignees: **The University of Chicago**, Chicago, IL (US); **Infectious Disease Research Institute**, Seattle, WA (US); **Paxvax, Inc.**, San Diego, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/823,668**

(22) PCT Filed: **Nov. 3, 2011**

(86) PCT No.: **PCT/US2011/059147**

§ 371 (c)(1),
(2), (4) Date: **Mar. 14, 2013**

(87) PCT Pub. No.: **WO2012/061599**

PCT Pub. Date: **May 10, 2012**

(65) **Prior Publication Data**

US 2013/0273094 A1 Oct. 17, 2013

Related U.S. Application Data

(60) Provisional application No. 61/456,309, filed on Nov. 4, 2010.

(51) **Int. Cl.**

A61K 39/00 (2006.01)
A61K 39/39 (2006.01)
A61K 39/002 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 39/002** (2013.01); **A61K 2039/55572** (2013.01); **A61K 2039/6031** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2004/0248113 A1 12/2004 Sette et al.
2009/0215087 A1 8/2009 Hill et al.

FOREIGN PATENT DOCUMENTS

FR WO2007125209 A1 * 11/2007 C07K 14/45
WO WO 0143768 A2 * 6/2001

OTHER PUBLICATIONS

Tan et al. 2010 (Identification of *T. gondii* epitopes, adjuvants, and host genetic factors that influence protection of mice and humans; Vaccine 28:3977-3989).*

Tan et al. 2010 (Identification of *T. gondii* epitopes, adjuvants, and host genetic factors that influence protection of mice and humans; Vaccine; 28:3977-3989).*

Boothroyd 2009 (*Toxoplasma gondii*: 25 years and 25 major advances for the field; International Journal for Parasitology 39:935-946).*

Lekutis et al. 2000 (*Toxoplasma gondii*: Identification of a Developmentally Regulated Family of genes related to SAG2; Experimental Parasitology 96:89-96).*

Khan et al. 2009 (Selection at a Single Locus Leads to Widespread Expansion of *Toxoplasma gondii* Lineages that are Virulent in Mice; PLoS Genetics 5(3):1-14).*

Alexander et al. 2000 (Linear PADRE T Helper Epitope and Carbohydrate B Cell Epitope Conjugates Induce Specific High Titer IgG Antibody Responses; The Journal of Immunology, 164:1625-1633).*

Sousa et al. 2009 (Selection of polymorphic peptides from GRA6 and GRA7 sequences *Toxoplasma gondii* strains to be used in serotyping; Clin Vaccine Immunol; 16(8):1158-69).*

Burg et al. 1989 (Direct and Sensitive Detection of a Pathogenic Protozoan, *Toxoplasma gondii* by Polymerase Chain Reaction; J Clin Microbiol 27(8): 1787-1792).*

Bui et al., "Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines," BMC Bioinformatics, 8(361): 1-6 (2007).

Cheng et al., "Relationship Between the Inhibition Constant (K_i) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I_{50}) of an Enzymatic Reaction," Biochem. Pharmac., 22:3099-3108 (1973).

Cong et al., Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8⁺T cell epitope based, adjuvanted vaccine protective against *Toxoplasma gondii*, Immunome Res., 6(12): 1-15 (2010).

Cong et al., "Towards an immunosense vaccine to prevent toxoplasmosis: Protective *Toxoplasma gondii* epitopes restricted by HLA-A*0201," Vaccine, 29: 754-762 (2011).

Cong et al., "*Toxoplasma gondii* HLA-B*0702-restricted GRA720-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8⁺T cells producing interferon- γ and reduces parasite burden in HLA-B*0702 mice," Human Immunol., 73:1-10 (2012).

Dzierszinski et al., "Targeted disruption of the glycosylphosphatidylinositol-anchored surface antigen SAG3 gene in *Toxoplasma gondii* decreases host cell adhesion and drastically reduces virulence in mice," *Toxoplasma gondii SAG3 mutants*, 37(3): 574-582 (2000).

(Continued)

Primary Examiner — Gary Nickol

Assistant Examiner — Mary Lyons

(74) *Attorney, Agent, or Firm* — McDonnell Boehnen Hulbert & Berghoff LLP

(57)

ABSTRACT

Vaccines are disclosed against parasites. The vaccines include peptides in an immunological composition. In particular, the parasite is *Toxoplasma gondii*.